EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Narsoplimab Results in Excellent Survival in Adults and Children With Hematopoietic Cell Transplant Associated Thrombotic Microangiopathy ( TA ‐ TMA )

Michelle L Schoettler iD, Sunil Kumar Pusarla, Narinder Nangia, Miguel-Angel Perales, Rafael F Duarte, Andreas Grauer, Alessandro Rambaldi iD

American Journal of Hematology · 2025-11 · 100 (11) · 2040-2051

DOI: 10.1002/ajh.70044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 29.08.2025. Verfasst von Michelle L Schoettler und 6 weiteren Autor:innen. Beteiligte Einrichtung: Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, USA. Hauptthemen laut MEDLINE: Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, American Society of Hematology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inappropriate complement activation is a key driver of hematopoietic cell transplant‐associated thrombotic microangiopathy (TA‐TMA). Treatment with narsoplimab, an inhibitor of MASP‐2, the effector enzyme of the lectin pathway, resulted in a response rate of 61% in a Phase 2 clinical trial in adults with TA‐TMA. Given these promising results, a global expanded access program (EAP) was established facilitating compassionate use treatment. Herein, we report the survival of children (< 16 years old) and adults (≥ 16 years old) enrolled in the EAP from October 2017 to October 2023 ( n = 136). Among children ( n = 50), the majority underwent allogeneic HCT ( n = 44); 37 were considered high‐risk (HR) and 30 (81.1%) had organ dysfunction at the time of TA‐TMA diagnosis. One‐year overall survival (OS) in pediatric allogeneic recipients with HR TA‐TMA who received narsoplimab as first‐line therapy ( n = 12) was 75.0% and 56.2% in those who received treatment as ≥ second‐line ( n = 25, 20 refractory to eculizumab). One‐year OS in the six children with a solid tumor who underwent an autologous HCT was 80%. Among the 86 adults, 84 received an allogeneic HCT, 65 had HR TA‐TMA and, among them, 57 (87.7%) had organ dysfunction at diagnosis. One‐year OS in allogeneic adults with HR TA‐TMA who received narsoplimab as first line therapy ( n = 49) was 58.0%, and 40.5% in those who received narsoplimab as ≥ second line therapy ( n = 16). There were no concerning safety signals. In this real‐world study enriched with patients with severe TA‐TMA, survival was excellent in children and adults, supporting the use of narsoplimab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thrombotic MicroangiopathiesHematopoietic Stem Cell TransplantationAntibodies, Monoclonal, HumanizedHumansChildAdolescentMaleAdultFemaleChild, PreschoolYoung AdultMiddle AgedSurvival RateInfant

Stichwörter der Autor:innen

hematopoietic cell transplantationmortalitynarsoplimabtransplant associated thrombotic microangiopathy

Substanzen

Antibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, USA.
  • Omeros Corporation, Seattle, Washington, USA.
  • Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
  • Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
  • Department of Oncology and Hematology, University of Milan and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII,Piazza OMS, Bergamo, Italy.

ORCID-Profile: Michelle L Schoettler, Alessandro Rambaldi

Förderung

  • NCI NIH HHS
  • American Society of Hematology

Zitieren

APA

Schoettler, M. L., Pusarla, S. K., Nangia, N., Perales, M. A., Duarte, R. F., Grauer, A., & Rambaldi, A. (2025). Narsoplimab Results in Excellent Survival in Adults and Children With Hematopoietic Cell Transplant Associated Thrombotic Microangiopathy ( TA ‐ TMA ). American Journal of Hematology, 100(11), 2040-2051. https://doi.org/10.1002/ajh.70044

Vancouver

Schoettler ML, Pusarla SK, Nangia N, Perales MA, Duarte RF, Grauer A, et al. Narsoplimab Results in Excellent Survival in Adults and Children With Hematopoietic Cell Transplant Associated Thrombotic Microangiopathy ( TA ‐ TMA ). American Journal of Hematology. 2025;100(11):2040-2051. doi:10.1002/ajh.70044

BibTeX
@article{Schoettler2025,
  author = {Schoettler, Michelle L and Pusarla, Sunil Kumar and Nangia, Narinder and Perales, Miguel-Angel and Duarte, Rafael F and Grauer, Andreas and Rambaldi, Alessandro},
  title = {Narsoplimab Results in Excellent Survival in Adults and Children With Hematopoietic Cell Transplant Associated Thrombotic Microangiopathy ( TA ‐ TMA )},
  journal = {American Journal of Hematology},
  year = {2025},
  volume = {100},
  number = {11},
  pages = {2040--2051},
  doi = {10.1002/ajh.70044}
}
Kostenlos starten →